Citizens Jmp Initiates Coverage on Kalaris Therapeutics (NASDAQ:KLRS)

Investment analysts at Citizens Jmp began coverage on shares of Kalaris Therapeutics (NASDAQ:KLRS) in a research note issued on Monday, MarketBeat.com reports. The firm set a “market outperform” rating and a $20.00 price target on the stock. Citizens Jmp’s price objective would suggest a potential upside of 324.63% from the stock’s current price.

Other research analysts also recently issued research reports about the stock. Wall Street Zen upgraded shares of Kalaris Therapeutics to a “hold” rating in a report on Friday, October 3rd. Citigroup began coverage on shares of Kalaris Therapeutics in a report on Monday. They set an “outperform” rating on the stock. Raymond James Financial began coverage on shares of Kalaris Therapeutics in a report on Tuesday, September 2nd. They set a “strong-buy” rating on the stock. Weiss Ratings restated a “sell (e)” rating on shares of Kalaris Therapeutics in a report on Wednesday, October 8th. Finally, Piper Sandler set a $3.00 price target on shares of Kalaris Therapeutics and gave the company a “neutral” rating in a report on Wednesday, July 23rd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Kalaris Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $11.50.

Kalaris Therapeutics Price Performance

KLRS stock opened at $4.71 on Monday. The company has a market capitalization of $88.08 million, a P/E ratio of -1.16 and a beta of 0.42. Kalaris Therapeutics has a 12 month low of $2.14 and a 12 month high of $23.69. The business has a 50 day simple moving average of $4.93.

Kalaris Therapeutics (NASDAQ:KLRS) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.10).

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of KLRS. XTX Topco Ltd bought a new position in Kalaris Therapeutics in the 2nd quarter worth $65,000. Fortis Capital Advisors LLC acquired a new stake in Kalaris Therapeutics in the 3rd quarter worth $231,000. Finally, Belpointe Asset Management LLC acquired a new stake in Kalaris Therapeutics in the 3rd quarter worth $231,000. Institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.